TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Oct 11

PMID 36218325

Authors

Naval G Daver

Abhishek Maiti

Tapan M Kadia

Paresh Vyas

Ravindra Majeti

Andrew H Wei

Guillermo Garcia-Manero

Charles Craddock

David A Sallman

Hagop M Kantarjian

Affiliations

Soon will be listed here.

Abstract

Significance: Emerging data on the impact of cytogenetic aberrations, TP53 allelic burden, immunobiology, and tumor microenvironment of TP53-mutated MDS and AML are further unraveling the complexity of this disease. An improved understanding of the functional consequences of TP53 mutations and immune dysregulation in TP53-mutated AML/MDS coupled with dismal outcomes has resulted in a shift from the use of cytotoxic and hypomethylating agent-based therapies to novel immune and nonimmune strategies for the treatment of this entity. It is hoped that these novel, rationally designed combinations will improve outcomes in this area of significant unmet need.

Citing Articles

Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study.

Benyahia S, Kahlon S, Paul S, Aboul-Nasr Y, Harvey K, Patel M Cureus. 2025; 17(2):e78491.

PMID: 40051959 PMC: 11884420. DOI: 10.7759/cureus.78491.

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.

Ma J, Sun S, Xie Y, Zhou S, Wu M, Zuo X Blood Cancer J. 2025; 15(1):19.

PMID: 39948069 PMC: 11825841. DOI: 10.1038/s41408-025-01228-6.

The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes.

Wang W, Zhang Y, Yang W, Liu X, Jiang L, Lang W J Transl Med. 2025; 23(1):76.

PMID: 39819628 PMC: 11740646. DOI: 10.1186/s12967-024-05995-x.

Conventional chemotherapy: millions of cures, unresolved therapeutic index.

Letai A, de The H Nat Rev Cancer. 2024; 25(3):209-218.

PMID: 39681637 DOI: 10.1038/s41568-024-00778-4.

Acute myeloid leukemia management and research in 2025.

Kantarjian H, DiNardo C, Kadia T, Daver N, Altman J, Stein E CA Cancer J Clin. 2024; 75(1):46-67.

PMID: 39656142 PMC: 11745214. DOI: 10.3322/caac.21873.

References

Guo G, Yu M, Xiao W, Celis E, Cui Y . Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Res. 2017; 77(9):2292-2305. PMC: 5465961. DOI: 10.1158/0008-5472.CAN-16-2832. View

Olivier M, Eeles R, Hollstein M, Khan M, Harris C, Hainaut P . The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19(6):607-14. DOI: 10.1002/humu.10081. View

Uy G, Aldoss I, Foster M, Sayre P, Wieduwilt M, Advani A . Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2020; 137(6):751-762. PMC: 7885824. DOI: 10.1182/blood.2020007732. View

Vadakekolathu J, Lai C, Reeder S, Church S, Hood T, Lourdusamy A . TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020; 4(20):5011-5024. PMC: 7594389. DOI: 10.1182/bloodadvances.2020002512. View

Chichili G, Huang L, Li H, Burke S, He L, Tang Q . A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015; 7(289):289ra82. DOI: 10.1126/scitranslmed.aaa5693. View

Klimovich B, Merle N, Neumann M, Elmshauser S, Nist A, Mernberger M . p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene. 2021; 41(7):1011-1023. PMC: 8837531. DOI: 10.1038/s41388-021-02141-5. View

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View

Donehower L, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M . Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019; 28(5):1370-1384.e5. PMC: 7546539. DOI: 10.1016/j.celrep.2019.07.001. View

Vergez F, Green A, Tamburini J, Sarry J, Gaillard B, Cornillet-Lefebvre P . High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011; 96(12):1792-8. PMC: 3232261. DOI: 10.3324/haematol.2011.047894. View

10.

Minculescu L, Marquart H, Ryder L, Andersen N, Schjoedt I, Friis L . Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. Front Immunol. 2019; 10:1997. PMC: 6714591. DOI: 10.3389/fimmu.2019.01997. View

11.

Nechiporuk T, Kurtz S, Nikolova O, Liu T, Jones C, DAlessandro A . The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925. PMC: 6606338. DOI: 10.1158/2159-8290.CD-19-0125. View

12.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

13.

Chen S, Wu J, Liang Y, Tang Y, Song H, Wu L . Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell. 2020; 39(2):225-239.e8. DOI: 10.1016/j.ccell.2020.11.013. View

14.

Hunter A, Sallman D . Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019; 32(2):134-144. DOI: 10.1016/j.beha.2019.05.004. View

15.

Duffy M, Synnott N, OGrady S, Crown J . Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020; 79:58-67. DOI: 10.1016/j.semcancer.2020.07.005. View

16.

Deniger D, Pasetto A, Robbins P, Gartner J, Prickett T, Paria B . T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res. 2018; 24(22):5562-5573. PMC: 6239943. DOI: 10.1158/1078-0432.CCR-18-0573. View

17.

Lode L, Menard A, Flet L, Richebourg S, Loirat M, Eveillard M . Emergence and evolution of mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica. 2017; 103(4):e143-e146. PMC: 5865441. DOI: 10.3324/haematol.2017.181404. View

18.

Hunter A, Sallman D . Targeting TP53 Mutations in Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020; 34(2):421-440. DOI: 10.1016/j.hoc.2019.11.004. View

19.

Zeidan A, Boss I, Beach C, Copeland W, Thompson E, Fox B . A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2021; 6(7):2207-2218. PMC: 9006291. DOI: 10.1182/bloodadvances.2021005487. View

20.

Thijssen R, Diepstraten S, Moujalled D, Chew E, Flensburg C, Shi M . Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021; 137(20):2721-2735. PMC: 8138548. DOI: 10.1182/blood.2020010167. View